Boston Sci Puts up $4B for BTG

The Marlborough, MA-based company hasn’t been shy about building up its portfolio through M&A, the only question now is can it slip in another deal before the end of the year.

Boston Scientific is back on the M&A trail. This time the Marlborough, MA-based company is offering $4 billion to acquire BTG in a deal set to close in the first half of 2019.

London-based BTG has three key businesses, the largest of which is its Interventional Medicine portfolio which encompasses several peripheral interventional product lines. The interventional oncology franchise includes the TheraSphere Y-90 radiotherapy microspheres and the GALIL cryoablation system, used to treat patients with liver, kidney and other cancers.

BTG’s Interventional Medicine business also has a highly-differentiated vascular portfolio, including filters, crossing catheters, microfoam and the EKOS Endovascular System. The EKOS system, in combination with clot-dissolving drugs, breaks down blood clots to restore blood flow in patients with pulmonary emboli, deep vein thrombosis and peripheral arterial occlusions. It was the first device cleared by the FDA for the treatment of pulmonary embolism – a common complication of hospitalization and a leading cause of preventable hospital deaths.

The BTG portfolio also includes a pharmaceutical business comprised of acute care antidotes to treat overexposure to certain medications and toxins, and a licensing business that receives royalties relating to products subject to BTG intellectual property and license agreements.

“The acquisition of BTG and its rapidly growing peripheral interventional portfolio is an exciting extension of our category leadership strategy that will augment our capabilities in important areas of unmet need such as cancer and pulmonary embolism,” Mike Mahoney, chairman and CEO of, Boston Scientific said in a release. "We are confident that the addition of these therapies to our portfolio will ultimately advance patient care in ways that could not be realized by either company alone, while also allowing us to realize substantial revenue and cost synergies and provide a strong return for investors."

Boston Scientific has kept the M&A fires warm this year, averaging almost a deal a month. Late last month, Boston Scientific’s CFO said the company still had ample opportunity for acquisitions.

BTG has been busy on the M&A trail itself. In September, the company acquired Novate Medical for about $20 million in cash with the potential for an additional $130 million in milestones.

Filed Under
500 characters remaining